Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Average PT from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $6.17.

A number of research firms recently commented on CNTX. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities began coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday, March 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX opened at $0.79 on Monday. The company has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $1.40. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75. The company has a market capitalization of $70.95 million, a price-to-earnings ratio of -0.87 and a beta of 2.06.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several large investors have recently modified their holdings of the stock. Shay Capital LLC purchased a new stake in shares of Context Therapeutics in the fourth quarter worth approximately $52,000. MPM Bioimpact LLC bought a new position in Context Therapeutics in the 4th quarter valued at $15,441,000. Millennium Management LLC lifted its position in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after purchasing an additional 34,835 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter valued at $31,000. Finally, Allostery Investments LP bought a new position in shares of Context Therapeutics in the fourth quarter worth about $998,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.